← Back to All US Stocks

Iqvia Holdings Inc.. (IQV) Stock Fundamental Analysis & AI Rating 2026

IQV NYSE Services-Commercial Physical & Biological Research DE CIK: 0001478242
Recently Updated • Analysis: May 7, 2026 • SEC Data: 2026-03-31
Combined AI Rating
BUY
63% Confidence
AGREEMENT
HOLD
50% Conf
BUY
76% Conf

📊 IQV Key Takeaways

Revenue: $4.2B
Net Margin: 6.6%
Free Cash Flow: $491.0M
Current Ratio: 0.75x
Debt/Equity: 2.25x
EPS: $1.61
AI Rating: HOLD with 50% confidence
Iqvia Holdings Inc.. (IQV) receives a BUY rating with 63% confidence from our AI fundamental analysis based on SEC 10-K filings. With revenue of $4.2B, net profit margin of 6.6%, and return on equity (ROE) of 4.4%, Iqvia Holdings Inc.. demonstrates strong fundamentals in the Healthcare sector. Below is our complete IQV stock analysis for 2026.

Is Iqvia Holdings Inc.. (IQV) a Good Investment?

Claude

IQVIA demonstrates solid operational fundamentals with 5.9% revenue growth, exceptional 62.8% gross margins, and strong $491M free cash flow generation. However, these strengths are undermined by aggressive leverage (2.25x debt/equity), weak liquidity (0.75x current ratio), and poor shareholder returns (4.4% ROE, 0.9% ROA), indicating capital structure mismanagement that erodes value despite operational quality.

ChatGPT

IQVIA shows solid fundamental quality with mid-single-digit revenue growth, stable net income, expanding per-share earnings, and strong free cash flow generation. Profitability is healthy for its industry, with double-digit operating margins and strong returns on equity, but the balance sheet remains the main constraint given high leverage, weak current liquidity, and only moderate interest coverage.

Why Buy Iqvia Holdings Inc.. Stock? IQV Key Strengths

Claude
  • + Strong gross margins of 62.8% indicating pricing power and quality service business model
  • + Consistent revenue growth of 5.9% YoY demonstrating market demand
  • + Robust free cash flow generation of $491M with 11.8% FCF margin providing financial flexibility
ChatGPT
  • + Consistent revenue growth supported by solid operating margin and resilient net margin
  • + Strong cash generation with $2.05B in free cash flow and a 12.6% FCF margin
  • + Healthy profitability profile, including 20.9% ROE and diluted EPS growth ahead of net income growth

IQV Stock Risks: Iqvia Holdings Inc.. Investment Risks

Claude
  • ! Critical liquidity stress with current ratio of 0.75x (current liabilities exceed current assets)
  • ! Excessive leverage at 2.25x debt/equity with thin 2.7x interest coverage creating refinancing vulnerability
  • ! Net income essentially flat despite revenue growth (-0.1% YoY), with net margin (6.6%) significantly below operating margin (12.4%), indicating heavy interest expense burden destroying profitability
ChatGPT
  • ! High leverage with debt-to-equity of 2.14x and $13.88B of long-term debt
  • ! Tight liquidity profile with current and quick ratios both at 0.75x
  • ! Interest coverage of 3.0x leaves less room if rates stay high or operating income weakens

Key Metrics to Watch

Claude
  • * Debt-to-equity trajectory and deleveraging progress
  • * Operating cash flow sustainability and working capital trends
  • * Net income growth relative to revenue growth to assess interest burden impact
ChatGPT
  • * Debt reduction and interest coverage improvement
  • * Sustained revenue growth translating into net income and free cash flow expansion

Iqvia Holdings Inc.. (IQV) Financial Metrics & Key Ratios

Revenue
$4.2B
Net Income
$274.0M
EPS (Diluted)
$1.61
Free Cash Flow
$491.0M
Total Assets
$29.7B
Cash Position
$1.9B

💡 AI Analyst Insight

The current ratio below 1.0x warrants monitoring of short-term liquidity.

IQV Profit Margin, ROE & Profitability Analysis

Gross Margin 62.8%
Operating Margin 12.4%
Net Margin 6.6%
ROE 4.4%
ROA 0.9%
FCF Margin 11.8%

IQV vs Healthcare Sector: How Iqvia Holdings Inc.. Compares

How Iqvia Holdings Inc.. compares to Healthcare sector averages

Net Margin
IQV 6.6%
vs
Sector Avg 12.0%
IQV Sector
ROE
IQV 4.4%
vs
Sector Avg 15.0%
IQV Sector
Current Ratio
IQV 0.7x
vs
Sector Avg 2.0x
IQV Sector
Debt/Equity
IQV 2.2x
vs
Sector Avg 0.6x
IQV Sector

Sector benchmarks are approximate industry averages. Actual sector performance may vary.

Is Iqvia Holdings Inc.. Stock Overvalued? IQV Valuation Analysis 2026

Based on fundamental analysis, Iqvia Holdings Inc.. shows some fundamental concerns relative to the Healthcare sector in 2026.

Return on Equity
4.4%
Sector avg: 15%
Net Profit Margin
6.6%
Sector avg: 12%
Revenue Growth
N/A
Year-over-year
Debt/Equity
2.25x
Sector avg: 0.6x

Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.

Iqvia Holdings Inc.. Balance Sheet: IQV Debt, Cash & Liquidity

Current Ratio
0.75x
Quick Ratio
0.75x
Debt/Equity
2.25x
Debt/Assets
78.6%
Interest Coverage
2.68x
Long-term Debt
$14.0B

IQV Revenue & Earnings Growth: 5-Year Financial Trend

IQV 5-year financial data: Year 2021: Revenue $13.9B, Net Income $191.0M, EPS $0.96. Year 2022: Revenue $14.4B, Net Income $279.0M, EPS $1.43. Year 2023: Revenue $15.0B, Net Income $966.0M, EPS $4.95. Year 2024: Revenue $15.4B, Net Income $1.1B, EPS $5.72. Year 2025: Revenue $16.3B, Net Income $1.4B, EPS $7.29.
Revenue
Net Income
EPS (right axis)

5-Year Trend Summary: Iqvia Holdings Inc..'s revenue has grown significantly by 18% over the 5-year period, indicating strong business expansion. The most recent EPS of $7.29 reflects profitable operations.

IQV Revenue Growth, EPS Growth & YoY Performance

Revenue Growth
N/A
Year-over-year
Net Income Growth
N/A
Year-over-year
EPS Growth
N/A
Earnings per share
FCF Margin
11.8%
Free cash flow / Revenue

IQV Quarterly Earnings & Performance

Quarterly financial performance data for Iqvia Holdings Inc.. including revenue, net income, and earnings per share.
Quarter Revenue Net Income EPS
Q1 2026 $3.8B $249.0M $1.40
Q3 2025 $3.9B $285.0M $1.55
Q2 2025 $3.8B $266.0M $1.54
Q1 2025 $3.7B $249.0M $1.40
Q3 2024 $3.7B $285.0M $1.55
Q2 2024 $3.7B $297.0M $1.59
Q1 2024 $3.7B $288.0M $1.53
Q3 2023 $3.6B $283.0M $1.49

Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.

Iqvia Holdings Inc.. Dividends, Buybacks & Capital Allocation

Operating Cash Flow
$618.0M
Cash generated from operations
Stock Buybacks
$552.0M
Shares repurchased (TTM)
Capital Expenditures
$127.0M
Investment in assets
Dividends Paid
$567.9M
Returned to shareholders

IQV SEC Filings: Latest 10-K & 10-Q Analysis

Access official SEC EDGAR filings for Iqvia Holdings Inc.. (CIK: 0001478242)

📋 Recent SEC Filings

Date Form Document Action
May 11, 2026 4 xslF345X06/wk-form4_1778533671.xml View →
May 11, 2026 4 xslF345X06/wk-form4_1778533645.xml View →
May 11, 2026 4 xslF345X06/wk-form4_1778533610.xml View →
May 11, 2026 4 xslF345X06/wk-form4_1778533546.xml View →
May 7, 2026 8-K d114471d8k.htm View →

Frequently Asked Questions about IQV

What is the AI rating for IQV?

Iqvia Holdings Inc.. (IQV) has a Combined AI Rating of BUY from Claude (HOLD) and ChatGPT (BUY) with 63% combined confidence, based on fundamental analysis of SEC EDGAR filings.

What are IQV's key strengths?

Claude: Strong gross margins of 62.8% indicating pricing power and quality service business model. Consistent revenue growth of 5.9% YoY demonstrating market demand. ChatGPT: Consistent revenue growth supported by solid operating margin and resilient net margin. Strong cash generation with $2.05B in free cash flow and a 12.6% FCF margin.

What are the risks of investing in IQV?

Claude: Critical liquidity stress with current ratio of 0.75x (current liabilities exceed current assets). Excessive leverage at 2.25x debt/equity with thin 2.7x interest coverage creating refinancing vulnerability. ChatGPT: High leverage with debt-to-equity of 2.14x and $13.88B of long-term debt. Tight liquidity profile with current and quick ratios both at 0.75x.

What is IQV's revenue and growth?

Iqvia Holdings Inc.. reported revenue of $4.2B.

Does IQV pay dividends?

Iqvia Holdings Inc.. pays dividends, with $567.9M distributed to shareholders in the trailing twelve months.

Where can I find IQV SEC filings?

Official SEC filings for Iqvia Holdings Inc.. (CIK: 0001478242) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.

What is IQV's EPS?

Iqvia Holdings Inc.. has a diluted EPS of $1.61.

How is the AI analysis conducted?

Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.

Is IQV a good stock to buy right now?

Based on our AI fundamental analysis in May 2026, Iqvia Holdings Inc.. has a BUY rating with 63% confidence. The AI analysis suggests favorable fundamentals based on SEC filings. This is not investment advice.

Is IQV stock overvalued or undervalued?

Valuation metrics for IQV: ROE of 4.4% (sector avg: 15%), net margin of 6.6% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.

Should I buy IQV stock in 2026?

Our dual AI analysis gives Iqvia Holdings Inc.. a combined BUY rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.

What is IQV's free cash flow?

Iqvia Holdings Inc..'s operating cash flow is $618.0M, with capital expenditures of $127.0M. FCF margin is 11.8%.

How does IQV compare to other Healthcare stocks?

Vs Healthcare sector averages: Net margin 6.6% (avg: 12%), ROE 4.4% (avg: 15%), current ratio 0.75 (avg: 2).

Is Iqvia Holdings Inc.. carrying too much debt?

IQV has a debt-to-equity ratio of 2.25x, which is above the Healthcare sector average of 0.6x. Combined with a current ratio below 1, this warrants careful monitoring of the balance sheet.

Top Rated Stocks
AAPL 92% MSFT 92% FAST 92% DT 92% DECK 92% DAVEW 92% CTAS 92% CRUS 92% CRMD 92% CRDO 92%
Sector: All Healthcare Stocks →
Browse: Buy Stocks
Disclaimer: This analysis is generated by Claude AI (Anthropic) and ChatGPT (OpenAI) based on publicly available SEC EDGAR filings. It does not include stock price data and should not be considered financial advice. All fundamental data is sourced from SEC public domain filings. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.
Data Source: SEC EDGAR | Analysis Date: May 7, 2026 | Data as of: 2026-03-31 | Powered by Claude AI